Everolimus
Phase 2TerminatedDevelopment Stage
Estrogen Receptor-positive Breast Cancer
Estrogen Receptor-positive Breast Cancer, Gastrinoma, Glucagonoma, HER2-negative Breast Cancer, Insulinoma, Mucositis, Oral Complications, Pancreatic Polypeptide Tumor, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Islet Cell Carcinoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Renal Cell Cancer
Nov 1, 2014 → Dec 1, 2015
About Everolimus
Everolimus is a phase 2 stage product being developed by Novartis for Estrogen Receptor-positive Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02273752. Target conditions include Estrogen Receptor-positive Breast Cancer, Gastrinoma, Glucagonoma.
Hype Score Breakdown
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00655252 | Pre-clinical | Completed |
| NCT05108740 | Pre-clinical | Completed |
| NCT05252585 | Approved | Active |
| NCT03525834 | Approved | Completed |
| NCT02962414 | Phase 3 | Active |
| NCT02842749 | Approved | Completed |
| NCT02429869 | Approved | Completed |
| NCT02539459 | Phase 2 | Terminated |
| NCT02687958 | Phase 2 | UNKNOWN |
| NCT02376985 | Phase 3 | Completed |
| NCT02338609 | Approved | Completed |
| NCT02236572 | Phase 2 | Terminated |
| NCT02273752 | Phase 2 | Terminated |
| NCT02201212 | Phase 2 | Completed |
| NCT01864070 | Phase 1 | Withdrawn |
| NCT01997255 | Phase 2 | Withdrawn |
| NCT02096107 | Approved | Completed |
| NCT02017860 | Phase 2 | Completed |
| NCT01636466 | Phase 3 | Terminated |
| NCT01609673 | Pre-clinical | Terminated |
Competing Products
20 competing products in Estrogen Receptor-positive Breast Cancer